Abstract
Inhaled long-acting bronchodilators (of β2-agonist or muscarinic antagonist type) or corticosteroids are used in stable chronic obstructive pulmonary disease (COPD) treatment in a step-up approach according to disease severity. Consequently, in more severe disease triple therapy with two bronchodilators and an inhaled corticosteroid can often be encountered in clinical practice, but its short-and long-term effects on disease outcomes are not very well known. The results of a study evaluating the short-term effects of budesonide/formoterol (inhaled corticosteroid/inhaled long-acting β2-agonist combination) and tiotropium (inhaled long-acting muscarinic antagonist) against tiotropium alone are analysed and discussed. On a short-term basis, triple therapy improves lung function, health status and disease morbidity irrespective of disease severity. Long-term benefits of triple inhaled therapy including the effects of its precocious use in less severe COPD subjects should be evaluated.
| Original language | English |
|---|---|
| Pages (from-to) | 1039-1042 |
| Number of pages | 4 |
| Journal | Expert Opinion on Pharmacotherapy |
| Volume | 11 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Apr 2010 |
Fingerprint
Keywords
- Budesonide/formoterol combination
- COPD
- Tiotropium
- Triple therapy
ASJC Scopus subject areas
- Pharmacology (medical)
- Pharmacology
Cite this
Triple inhaled therapy in stable chronic obstructive pulmonary disease : The earlier, the better? / Antoniu, Sabina Antonela; Carone, Mauro; Sampablo, Italo.
In: Expert Opinion on Pharmacotherapy, Vol. 11, No. 6, 04.2010, p. 1039-1042.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Triple inhaled therapy in stable chronic obstructive pulmonary disease
T2 - The earlier, the better?
AU - Antoniu, Sabina Antonela
AU - Carone, Mauro
AU - Sampablo, Italo
PY - 2010/4
Y1 - 2010/4
N2 - Inhaled long-acting bronchodilators (of β2-agonist or muscarinic antagonist type) or corticosteroids are used in stable chronic obstructive pulmonary disease (COPD) treatment in a step-up approach according to disease severity. Consequently, in more severe disease triple therapy with two bronchodilators and an inhaled corticosteroid can often be encountered in clinical practice, but its short-and long-term effects on disease outcomes are not very well known. The results of a study evaluating the short-term effects of budesonide/formoterol (inhaled corticosteroid/inhaled long-acting β2-agonist combination) and tiotropium (inhaled long-acting muscarinic antagonist) against tiotropium alone are analysed and discussed. On a short-term basis, triple therapy improves lung function, health status and disease morbidity irrespective of disease severity. Long-term benefits of triple inhaled therapy including the effects of its precocious use in less severe COPD subjects should be evaluated.
AB - Inhaled long-acting bronchodilators (of β2-agonist or muscarinic antagonist type) or corticosteroids are used in stable chronic obstructive pulmonary disease (COPD) treatment in a step-up approach according to disease severity. Consequently, in more severe disease triple therapy with two bronchodilators and an inhaled corticosteroid can often be encountered in clinical practice, but its short-and long-term effects on disease outcomes are not very well known. The results of a study evaluating the short-term effects of budesonide/formoterol (inhaled corticosteroid/inhaled long-acting β2-agonist combination) and tiotropium (inhaled long-acting muscarinic antagonist) against tiotropium alone are analysed and discussed. On a short-term basis, triple therapy improves lung function, health status and disease morbidity irrespective of disease severity. Long-term benefits of triple inhaled therapy including the effects of its precocious use in less severe COPD subjects should be evaluated.
KW - Budesonide/formoterol combination
KW - COPD
KW - Tiotropium
KW - Triple therapy
UR - http://www.scopus.com/inward/record.url?scp=77949891785&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77949891785&partnerID=8YFLogxK
U2 - 10.1517/14656561003652450
DO - 10.1517/14656561003652450
M3 - Article
VL - 11
SP - 1039
EP - 1042
JO - Expert Opinion on Pharmacotherapy
JF - Expert Opinion on Pharmacotherapy
SN - 1465-6566
IS - 6
ER -